Bone Biologics Corp: INTRACOASTAL CAPITAL, LLC amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
IntraCoastal Capital LLC has amended its Schedule 13G beneficial ownership filing for Bone Biologics Corp, disclosing its stake in the medical device developer to the SEC under accession number 0001213900-26-118156. The filing, submitted on the short-form schedule reserved for passive investors, updates the investment firm's position in the company without indicating any activist intent. The specific size and percentage of the holding were not detailed in the filing headline, leaving the exact change from prior disclosures unclear. Investors will watch for further 13G or 13D amendments to gauge whether IntraCoastal's position is growing or being trimmed, and for any accompanying Form 4 insider filings.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Bone Biologics Corp, Intracoastal Capital, LLC